A Phase 3 interventional study of Olanzapine and Fluoxetine in Treatment Resistant Depression, sponsored by Eli Lilly and Company. Terminated at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depressive Disorder, Treatment-Resistant with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · China.
Among the 30 studies in Depressive Disorder, Treatment-Resistant with a site in China, this one is the 7th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 3, and was the 1st registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →13 of the 30 studies in Depressive Disorder, Treatment-Resistant with a site in China are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in China, United States, Japan and 1 more country
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70
Tianjin Anding Hospital · Sites in China
Ages 18–55
West China Hospital · Sites in China
Ages 18–65
Changping Laboratory · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 60 across the 29 interventional studies, 162 across the 1 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Depressive Disorder, Treatment-Resistant with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks. Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.
Drug: Olanzapine · Drug: Fluoxetine
Placebo matches the Olanzapine tablet for blinding. Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.
Drug: Fluoxetine · Drug: Placebo
Administered Orally
Also known as: LY170053, Zyprexa
Administered Orally
Also known as: LY110140, Prozac
Administered Orally
Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)
The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. Least square means (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for treatment, Pooled Investigator, Visit, (Baseline + Treatment)\*Visit.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale
CGI-S scale measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The LS mean (LSM) change from baseline, standard error was derived using MMRM methodology with factors for treatment , Pooled Investigator , Visit , (Baseline + Treatment)\*Visit.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)
SAS scale consists of 10 items including 7 items that address bradykinesia-rigidity and additional single items for tremor, glabellar tap,and salivation. Each item represents a specific physical condition and is rated on a 5-point category rating scale ranging from 0 (complete absence of the condition) to 4 (the condition is present to an extreme degree).The total score is obtained by adding the scores for the 10 individual items making the maximum possible score is 40. Higher scores are indicative of more severe Parkinsonian-type symptoms.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)
SF-36, version 2 is a generic participant-rated questionnaire and consists of 36 questions covering the following 8 health domains (subscales): general health, role limitations because of physical problems, role limitations due to emotional problems, physical functioning, bodily pain, mental health, social functioning, and vitality. Each subscale is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) were constructed based on the eight SF-36 subscales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)
SDS consists of 3 items (work/school, social life/leisure activities, and family life/home responsibilities). Total scores range from 0 to 30 with higher values indicating greater disruption. Individual Item scores range from 0 to 10 with higher values indicating greater disruption.
Time frame: Baseline, 8 Weeks
Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score
The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.
Time frame: Baseline,8 Weeks
Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks
The MADRS consists of 10 items with each item rated on a scale ranging from 0 to 6. Fixed descriptors appear along the scale for each item at points 0, 2, 4, and 6, to standardize the gradation of response along the scale. The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)
BAS is used to rate observable, restless movements of drug induced akathisia and the subjective awareness of restlessness and any distress associated with the akathisia. The BAS consists of the following 3 items: an objective assessment of akathisia symptoms; a subjective assessment of the patient's awareness of inner restlessness; and a global clinical assessment of akathisia. The first two items are rated on a 4-point scale ranging from 0 (no abnormal movements or the absence of inner restlessness) to 3 (severe akathisia or the awareness of intense compulsion to move most of the time). The last item, the global clinical assessment of akathisia, is rated on a 5-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Total BAS score ranges from 0 to 14 with a higher score representing worse results.
Time frame: Baseline, 8 Weeks
Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
AIMS is a 12-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 and 12 are yes/no questions regarding the dental status of the participant. The total score is the sum of the scores for the 12 items and the possible total score ranges from 0 to 42. A higher total score is indicative of more severe dyskinetic movements.
Time frame: Baseline, 8 Weeks
| Milestone | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Started | 88 | 88 |
| Safety analysis set | 88 | 87 |
| Completed | 56 | 49 |
| Not completed | 32 | 39 |
| Withdrew: Adverse event | 3 | 10 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal by subject | 21 | 19 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Entry criteria not met | 6 | 2 |
The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. Least square means (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for treatment, Pooled Investigator, Visit, (Baseline + Treatment)\*Visit.
| Units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS) | -15.92 ± 1.20 | -14.30 ± 1.28 |
CGI-S scale measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The LS mean (LSM) change from baseline, standard error was derived using MMRM methodology with factors for treatment , Pooled Investigator , Visit , (Baseline + Treatment)\*Visit.
| Units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale | -1.43 ± 0.15 | -1.63 ± 0.16 |
SAS scale consists of 10 items including 7 items that address bradykinesia-rigidity and additional single items for tremor, glabellar tap,and salivation. Each item represents a specific physical condition and is rated on a 5-point category rating scale ranging from 0 (complete absence of the condition) to 4 (the condition is present to an extreme degree).The total score is obtained by adding the scores for the 10 individual items making the maximum possible score is 40. Higher scores are indicative of more severe Parkinsonian-type symptoms.
| units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS) | 0.03 ± 1.71 | -0.14 ± 1.72 |
SF-36, version 2 is a generic participant-rated questionnaire and consists of 36 questions covering the following 8 health domains (subscales): general health, role limitations because of physical problems, role limitations due to emotional problems, physical functioning, bodily pain, mental health, social functioning, and vitality. Each subscale is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) were constructed based on the eight SF-36 subscales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.
| units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Physical Functioning | 2.20 ± 7.51 | 0.70 ± 7.47 |
| Role-Physical | 3.99 ± 11.79 | 3.93 ± 11.23 |
| Bodily Pain | 6.81 ± 12.05 | 0.02 ± 11.30 |
| General Health | 5.82 ± 11.49 | 2.84 ± 9.44 |
| Vitality | 7.43 ± 13.54 | 5.04 ± 9.83 |
| Social Functioning | 6.13 ± 13.55 | 4.56 ± 11.78 |
| Role-Emotional | 6.61 ± 12.39 | 6.71 ± 12.12 |
| Mental Health | 8.98 ± 13.46 | 8.43 ± 11.99 |
| Mental Component Score | 8.87 ± 14.29 | 8.73 ± 12.54 |
| Physical Component Score | 2.87 ± 7.59 | -0.65 ± 7.22 |
SDS consists of 3 items (work/school, social life/leisure activities, and family life/home responsibilities). Total scores range from 0 to 30 with higher values indicating greater disruption. Individual Item scores range from 0 to 10 with higher values indicating greater disruption.
| Units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Work/School (n=68,65) | -1.34 ± 2.71 | -1.55 ± 2.89 |
| Social Life (n=79,79) | -1.70 ± 2.66 | -1.49 ± 2.85 |
| Family Life (n=79,78) | -1.63 ± 3.00 | -1.53 ± 2.66 |
| SDS Total Score (68,64) | -4.57 ± 7.75 | -4.41 ± 7.89 |
The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.
| Percent of participants | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score | 65.5 | 61.2 |
The MADRS consists of 10 items with each item rated on a scale ranging from 0 to 6. Fixed descriptors appear along the scale for each item at points 0, 2, 4, and 6, to standardize the gradation of response along the scale. The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.
| Percent of participants | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks | 37.9 | 38.8 |
BAS is used to rate observable, restless movements of drug induced akathisia and the subjective awareness of restlessness and any distress associated with the akathisia. The BAS consists of the following 3 items: an objective assessment of akathisia symptoms; a subjective assessment of the patient's awareness of inner restlessness; and a global clinical assessment of akathisia. The first two items are rated on a 4-point scale ranging from 0 (no abnormal movements or the absence of inner restlessness) to 3 (severe akathisia or the awareness of intense compulsion to move most of the time). The last item, the global clinical assessment of akathisia, is rated on a 5-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Total BAS score ranges from 0 to 14 with a higher score representing worse results.
| units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS) | -0.01 ± 2.24 | -0.04 ± 2.13 |
AIMS is a 12-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 and 12 are yes/no questions regarding the dental status of the participant. The total score is the sum of the scores for the 12 items and the possible total score ranges from 0 to 42. A higher total score is indicative of more severe dyskinetic movements.
| units on a scale | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS) | -0.16 ± 1.47 | -0.31 ± 3.28 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine + Fluoxetine | — | 1/88 (1.1%) | 55/88 (62.5%) |
| Placebo + Fluoxetine | — | 1/87 (1.1%) | 45/87 (51.7%) |
| Event | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| Suicide attemptPsychiatric disorders | 0/88 | 1/87 |
| RestlessnessPsychiatric disorders | 1/88 | 0/87 |
| Event | Olanzapine + Fluoxetine | Placebo + Fluoxetine |
|---|---|---|
| SomnolenceNervous system disorders | 15/88 | 3/87 |
| Blood prolactin increasedInvestigations | 9/88 | 2/87 |
| Weight increasedInvestigations | 8/88 | 2/87 |
| Alanine aminotransferase increasedInvestigations | 7/88 | 1/87 |
| Blood triglycerides increasedInvestigations | 7/88 | 3/87 |
| Hepatic function abnormalHepatobiliary disorders | 6/88 | 1/87 |
| Increased appetiteMetabolism and nutrition disorders | 6/88 | 1/87 |
| DizzinessNervous system disorders | 3/88 | 5/87 |
| Aspartate aminotransferase increasedInvestigations | 5/88 | 0/87 |
| Blood cholesterol increasedInvestigations | 5/88 | 1/87 |
All randomized participants.
| Age, Continuous(years) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Mean | 38.63 ± 12.18 | 41.45 ± 12.44 | 40.04 ± 12.36 |
| Sex: Female, Male(Participants) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Female | 41 | 36 | 77 |
| Male | 47 | 52 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 88 | 88 | 176 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 88 | 88 | 176 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| China | 88 | 88 | 176 |
| Montgomery-Äsberg Depression Rating Scale (MADRS) Total Score(units on a scale) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Mean | 32.1 ± 5.3 | 31.8 ± 4.8 | 32.0 ± 5.0 |
| 17 Item Hamilton Rating Scale for Depression (HAM-D17) Total Score(units on a scale) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Mean | 24.6 ± 2.6 | 25.0 ± 2.6 | 24.8 ± 2.6 |
| Clinical Global Impressions-Severity of Depression (CGI-S)(units on a scale) | Olanzapine + Fluoxetine | Placebo + Fluoxetine | Total |
|---|---|---|---|
| Mean | 4.9 ± 0.6 | 4.9 ± 0.7 | 4.9 ± 0.7 |
5 further baseline measures are reported on the registry.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Sep 2012, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine
Depressive Disorder, Treatment-Resistant →